Browse by author
Lookup NU author(s): Professor Nicola PaveseORCiD, Dr David Ledingham
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0).
© 2024 The Author(s). The prevalence of Parkinson’s disease has rapidly increased over the last decade. This editorial discusses our current understanding of the pathophysiological basis for the condition, with a particular focus on the potential role of α-synuclein, and the consequent implications this has for both the development of new investigations and disease-modifying therapies. Specifically, the article discusses the development of a new diagnostic test for cerebrospinal fluid α-synuclein, the development of a new staging system for Parkinson’s disease, which takes into account the α-synuclein, genetic and neuro-imaging status, and the results of two recently completed clinical trials, using monoclonal antibodies wherein α-synuclein is the principal target. We also discuss the increasing awareness of the importance of non-motor symptoms in Parkinson’s disease including hyposmia, rapid eye movement sleep behaviour disorder, and autonomic and cognitive symptoms.
Author(s): Pavese N, Ledingham D
Publication type: Review
Publication status: Published
Journal: British Journal of Hospital Medicine
Year: 2024
Volume: 85
Issue: 7
Online publication date: 30/07/2024
Acceptance date: 01/07/2024
ISSN (print): 1750-8460
ISSN (electronic): 1759-7390
Publisher: MA Healthcare Ltd
URL: https://doi.org/10.12968/hmed.2024.0313
DOI: 10.12968/hmed.2024.0313
PubMed id: 39078897
Data Access Statement: All the data of this study are included in this article.
